KYAT3 and breast cancer: Therefore, CCBL2 possesses a significant prognostic value for ER-positive BC patients with or after endocrine therapy, particularly in the subgroup receiving only endocrine therapy, but little prognostic value in the subgroup receiving both endocrine therapy and chemotherapy.